Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
190 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014', provides an overview of the Idiopathic Pulmonary Fibrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Idiopathic Pulmonary Fibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Idiopathic Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Idiopathic Pulmonary Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Idiopathic Pulmonary Fibrosis Overview 9 Therapeutics Development 10 Pipeline Products for Idiopathic Pulmonary Fibrosis - Overview 10 Pipeline Products for Idiopathic Pulmonary Fibrosis - Comparative Analysis 11 Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies 12 Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes 16 Idiopathic Pulmonary Fibrosis - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Idiopathic Pulmonary Fibrosis - Products under Development by Companies 20 Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes 23 Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development 24 Bristol-Myers Squibb Company 24 Boehringer Ingelheim GmbH 25 F. Hoffmann-La Roche Ltd. 26 Biogen Idec Inc. 27 Sanofi 28 GlaxoSmithKline plc 29 MedImmune, LLC 30 Gilead Sciences, Inc. 31 Vectura Group plc 32 Moerae Matrix, Inc. 33 FibroGen, Inc. 34 Chong Kun Dang Pharmaceutical Corp. 35 InterMune, Inc. 36 Celgene Corporation 37 IntelGenx Corp. 38 Compugen Ltd. 39 Pharmaxis Limited 40 ProMetic Life Sciences Inc. 41 HanAll Biopharma Co., Ltd. 42 LTT Bio-Pharma Co., Ltd. 43 Auspex Pharmaceuticals, Inc. 44 AdAlta Pty Ltd. 45 AnaptysBio, Inc. 46 Promedior, Inc. 47 Therametrics holding AG 48 MSM Protein Technologies, Inc. 49 GenKyoTex S.A. 50 iBio, Inc. 51 ImmuneWorks, LLC 52 Progenra, Inc. 53 Histocell S.L. 54 BiOrion Technologies B.V. 55 Pacific Therapeutics Ltd. 56 Corridor Pharmaceuticals Inc. 57 Lanthio Pharma B.V. 58 Kasiak Research Pvt. Ltd. 59 Idiopathic Pulmonary Fibrosis - Therapeutics Assessment 60 Assessment by Monotherapy Products 60 Assessment by Combination Products 61 Assessment by Target 62 Assessment by Mechanism of Action 66 Assessment by Route of Administration 70 Assessment by Molecule Type 72 Drug Profiles 74 pirfenidone - Drug Profile 74 nintedanib - Drug Profile 77 lebrikizumab - Drug Profile 80 vismodegib - Drug Profile 82 tralokinumab - Drug Profile 85 FG-3019 - Drug Profile 87 PC-SOD - Drug Profile 89 nintedanib - Drug Profile 90 STX-100 - Drug Profile 93 simtuzumab - Drug Profile 94 SAR-156597 - Drug Profile 96 BMS-986020 - Drug Profile 97 CKD-942 - Drug Profile 98 Refacell-IPF - Drug Profile 99 PXS-25 - Drug Profile 100 PXS-64 - Drug Profile 101 MMI-0100 - Drug Profile 102 PRM-151 - Drug Profile 103 IW-001 - Drug Profile 105 (pentoxifylline + acetylcysteine) - Drug Profile 106 omipalisib - Drug Profile 107 PBI-4050 - Drug Profile 108 CC-90001 - Drug Profile 109 interferon gamma-1b - Drug Profile 110 SD-560 - Drug Profile 111 CGEN-25009 - Drug Profile 112 PRM-151 - Drug Profile 113 GKT-137831 - Drug Profile 115 LP2 - Drug Profile 116 HL-156Fib - Drug Profile 117 INT-0024 - Drug Profile 118 C-301 - Drug Profile 119 pirfenidone - Drug Profile 120 TD-139 - Drug Profile 121 Small Molecule to Inhibit NOX 1 and 4 - Drug Profile 122 phytate sodium - Drug Profile 123 HR-017 - Drug Profile 124 Drug for Idiopathic Pulmonary Fibrosis - Drug Profile 125 BOT-191 - Drug Profile 126 Small Molecules to Inhibit LOXL2 for Oncology and Fibrosis - Drug Profile 127 Small Molecule for Idiopathic Pulmonary Fibrosis - Drug Profile 128 AM-0010 - Drug Profile 129 MSM-735 - Drug Profile 130 IBIOCFB-03 - Drug Profile 131 Monoclonal Antibody for Idiopathic Pulmonary Fibrosis - Drug Profile 132 RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis - Drug Profile 133 CC-539 - Drug Profile 134 KBP-7018 - Drug Profile 135 HC-016 - Drug Profile 136 Small Molecule 1 for Chronic Respiratory Diseases - Drug Profile 137 Small Molecule 2 for Chronic Respiratory Diseases - Drug Profile 138 DasKloster-0228-01 - Drug Profile 139 PXS-4820 - Drug Profile 140 Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile 141 Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis - Drug Profile 142 PBF-1250 - Drug Profile 143 Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile 144 Idiopathic Pulmonary Fibrosis - Recent Pipeline Updates 145 Idiopathic Pulmonary Fibrosis - Dormant Projects 174 Idiopathic Pulmonary Fibrosis - Discontinued Products 175 Idiopathic Pulmonary Fibrosis - Product Development Milestones 176 Featured News & Press Releases 176 Appendix 185 Methodology 185 Coverage 185 Secondary Research 185 Primary Research 185 Expert Panel Validation 185 Contact Us 186 Disclaimer 186
List of Tables Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2014 14 Number of Products under Development for Idiopathic Pulmonary Fibrosis - Comparative Analysis, H2 2014 15 Number of Products under Development by Companies, H2 2014 17 Number of Products under Development by Companies, H2 2014 (Contd..1) 18 Number of Products under Development by Companies, H2 2014 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2014 20 Comparative Analysis by Late Stage Development, H2 2014 21 Comparative Analysis by Clinical Stage Development, H2 2014 22 Comparative Analysis by Early Stage Development, H2 2014 23 Products under Development by Companies, H2 2014 24 Products under Development by Companies, H2 2014 (Contd..1) 25 Products under Development by Companies, H2 2014 (Contd..2) 26 Products under Investigation by Universities/Institutes, H2 2014 27 Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2014 28 Idiopathic Pulmonary Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H2 2014 29 Idiopathic Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 30 Idiopathic Pulmonary Fibrosis - Pipeline by Biogen Idec Inc., H2 2014 31 Idiopathic Pulmonary Fibrosis - Pipeline by Sanofi, H2 2014 32 Idiopathic Pulmonary Fibrosis - Pipeline by GlaxoSmithKline plc, H2 2014 33 Idiopathic Pulmonary Fibrosis - Pipeline by MedImmune, LLC, H2 2014 34 Idiopathic Pulmonary Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2014 35 Idiopathic Pulmonary Fibrosis - Pipeline by Vectura Group plc, H2 2014 36 Idiopathic Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H2 2014 37 Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H2 2014 38 Idiopathic Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 39 Idiopathic Pulmonary Fibrosis - Pipeline by InterMune, Inc., H2 2014 40 Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corporation, H2 2014 41 Idiopathic Pulmonary Fibrosis - Pipeline by IntelGenx Corp., H2 2014 42 Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd., H2 2014 43 Idiopathic Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H2 2014 44 Idiopathic Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2014 45 Idiopathic Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 46 Idiopathic Pulmonary Fibrosis - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2014 47 Idiopathic Pulmonary Fibrosis - Pipeline by Auspex Pharmaceuticals, Inc., H2 2014 48 Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H2 2014 49 Idiopathic Pulmonary Fibrosis - Pipeline by AnaptysBio, Inc., H2 2014 50 Idiopathic Pulmonary Fibrosis - Pipeline by Promedior, Inc., H2 2014 51 Idiopathic Pulmonary Fibrosis - Pipeline by Therametrics holding AG, H2 2014 52 Idiopathic Pulmonary Fibrosis - Pipeline by MSM Protein Technologies, Inc., H2 2014 53 Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H2 2014 54 Idiopathic Pulmonary Fibrosis - Pipeline by iBio, Inc., H2 2014 55 Idiopathic Pulmonary Fibrosis - Pipeline by ImmuneWorks, LLC, H2 2014 56 Idiopathic Pulmonary Fibrosis - Pipeline by Progenra, Inc., H2 2014 57 Idiopathic Pulmonary Fibrosis - Pipeline by Histocell S.L., H2 2014 58 Idiopathic Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2014 59 Idiopathic Pulmonary Fibrosis - Pipeline by Pacific Therapeutics Ltd., H2 2014 60 Idiopathic Pulmonary Fibrosis - Pipeline by Corridor Pharmaceuticals Inc., H2 2014 61 Idiopathic Pulmonary Fibrosis - Pipeline by Lanthio Pharma B.V., H2 2014 62 Idiopathic Pulmonary Fibrosis - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 63 Assessment by Monotherapy Products, H2 2014 64 Assessment by Combination Products, H2 2014 65 Number of Products by Stage and Target, H2 2014 68 Number of Products by Stage and Mechanism of Action, H2 2014 72 Number of Products by Stage and Route of Administration, H2 2014 75 Number of Products by Stage and Molecule Type, H2 2014 77 Idiopathic Pulmonary Fibrosis Therapeutics - Recent Pipeline Updates, H2 2014 149 Idiopathic Pulmonary Fibrosis - Dormant Projects, H2 2014 178 Idiopathic Pulmonary Fibrosis - Discontinued Products, H2 2014 179
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
